Predicted protein targets (top 18)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KMT2A | Q03164 | 3/20 | 0.64 |
| ▸ | MEN1 | O00255 | 2/20 | 0.64 |
| ▸ | ALDH1A1 | P00352 | 8/20 | 0.59 |
| ▸ | MAPT | P10636 | 4/20 | 0.57 |
| ▸ | KDM4E | B2RXH2 | 3/20 | 0.57 |
| ▸ | RAB9A | P51151 | 2/20 | 0.57 |
| ▸ | LMNA | P02545 | 2/20 | 0.57 |
| ▸ | HPGD | P15428 | 1/20 | 0.57 |
| ▸ | HRH3 | Q9Y5N1 | 1/20 | 0.56 |
| ▸ | MAPK1 | P28482 | 3/20 | 0.56 |
| ▸ | POLB | P06746 | 2/20 | 0.56 |
| ▸ | GAA | P10253 | 2/20 | 0.56 |
| ▸ | NSD2 | O96028 | 1/20 | 0.56 |
| ▸ | KDR | P35968 | 1/20 | 0.56 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.55 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.55 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.55 |
| ▸ | GSK3B | P49841 | 2/20 | 0.55 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4874296 | 0.93 | ALDH1A1 (0.71) | KMT2AMEN1ALDH1A1MAPTKDM4E | |
| SCHEMBL26921192 | 0.92 | ALDH1A1 (0.59) | KMT2AMEN1ALDH1A1MAPTRAB9A | |
| SCHEMBL26921592 | 0.91 | KMT2A (0.60) | KMT2AMEN1ALDH1A1MAPTKDM4E | |
| SCHEMBL4819694 | 0.91 | ALDH1A1 (0.69) | KMT2AMEN1ALDH1A1MAPTKDM4E | |
| SCHEMBL26921088 | 0.91 | ALDH1A1 (0.62) | KMT2AMEN1ALDH1A1MAPTKDM4E | |
| SCHEMBL4877367 | 0.88 | KMT2A (0.53) | KMT2AMEN1ALDH1A1MAPTKDM4E | |
| SCHEMBL5798719 | 0.87 | KMT2A (0.56) | KMT2AMEN1ALDH1A1MAPTKDM4E | |
| Hydrochloric Acid SCHEMBL4485907 | 0.86 | ALDH1A1 (0.80) | ALDH1A1MAPTKDM4ELMNAMAPK1 | |
| SCHEMBL21748552 | 0.85 | KMT2A (0.51) | KMT2AMEN1ALDH1A1MAPTKDM4E | |
| SCHEMBL4818305 | 0.84 | ALDH1A1 (0.60) | KMT2AMEN1ALDH1A1MAPTKDM4E |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9616051-B2 | Drug targets to overcome de novo drug-resistance in multiple myeloma | H. LEE MOFFITT CANCER CENTER AND RESEARCH INSTITUTE, INC. (US) | 2017-04-11 | — | — | US | disclosed |
| US-9616051-B2 | Drug targets to overcome de novo drug-resistance in multiple myeloma | H. LEE MOFFITT CANCER CENTER AND RESEARCH INSTITUTE, INC. (US) | 2017-04-11 | — | — | US | disclosed |
| US-20130281389-A1 | NOVEL DRUG TARGETS TO OVERCOME DE NOVO DRUG-RESISTANCE IN MULTIPLE MYELOMA | H. LEE MOFFITT CANCER CENTER AND RESEARCH INSTITUTE, INC. | 2013-10-24 | — | — | US | disclosed |
| US-20130281389-A1 | NOVEL DRUG TARGETS TO OVERCOME DE NOVO DRUG-RESISTANCE IN MULTIPLE MYELOMA | H. LEE MOFFITT CANCER CENTER AND RESEARCH INSTITUTE, INC. | 2013-10-24 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20130281389-A1 | NOVEL DRUG TARGETS TO OVERCOME DE NOVO DRUG-RESISTANCE IN MULTIPLE MYELOMA | XPO1, XPOT, DDB1 | KMT2A 2104/4885MEN1 362/4885ALDH1A1 4788/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.